Pharma’s Challenge to Drug Price Excise Tax Sits on Shaky Ground

The Chamber and PhRMA “face a pretty uphill climb here when it comes to the excessive fines clause arguments,” said Zachary Baron, an associate director of the Health Policy and the Law Initiative at Georgetown University’s O’Neill Institute.

Read more here.